MapLight Therapeutics, Inc. (MPLT)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
8.10 USD
+0.08
(0.998%)
⇧
(Oct. 16, 2026, 9:30 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:58 a.m. EDT
The investment case for MapLight Therapeutics has collapsed due to a catastrophic confluence of deteriorating clinical data and a broken balance sheet. The company recently suffered massive share price declines following mixed Phase 2 schizophrenia results, which shattered hopes for its core asset. Fundamentally, the business is in freefall with negative earnings, negative free cash flow, and a return on equity of -111%, indicating severe capital destruction. While the balance sheet currently shows low debt relative to cash, this is likely a temporary reprieve before inevitable dilution or restructuring is required to fund operations. The technical picture is equally grim, with the stock trading significantly below its 50-day and 200-day moving averages, confirming a long-term downtrend. Options activity reinforces this bearish view, with heavy put writing suggesting traders are betting on continued weakness. The disconnect between the 'strong buy' analyst recommendation and the reality of the business—negative growth, failed trials, and eroding value—is a classic value trap where the market has correctly priced out the future. There is no catalyst for recovery visible in the data; the company is burning cash without a proven product to generate returns. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.081913 |
| AutoTheta | 0.083517 |
| MSTL | 0.115526 |
| AutoARIMA | 0.207346 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.529 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.57 |
| Market Cap | 450,163,360 |
| Forward P/E | -2.37 |
| Website | https://www.maplightrx.com |
As of Oct. 10, 2026, 10:58 a.m. EDT: Speculators are positioning heavily for downside protection with deep out-of-the-money puts dominating open interest across multiple expirations, while call activity is sparse and concentrated at strikes far above the current price. This distribution suggests a market consensus expecting significant further declines rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.56270444 |
| Address1 | 800 Chesapeake Drive |
| All Time High | 40.43 |
| All Time Low | 7.46 |
| Ask | 10.59 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 420,770 |
| Average Daily Volume3 Month | 831,943 |
| Average Volume | 831,943 |
| Average Volume10Days | 420,770 |
| Bid | 5.69 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 7.666 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.1 |
| Current Ratio | 16.523 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 8.1 |
| Day Low | 8.1 |
| Debt To Equity | 0.57 |
| Display Name | MapLight Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -242,343,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.286 |
| Enterprise Value | 69,212,216 |
| Eps Current Year | -4.7 |
| Eps Forward | -3.41885 |
| Eps Trailing Twelve Months | -6.25 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.3208 |
| Fifty Day Average Change | -3.2207994 |
| Fifty Day Average Change Percent | -0.2845028 |
| Fifty Two Week Change Percent | -56.270443 |
| Fifty Two Week High | 40.43 |
| Fifty Two Week High Change | -32.33 |
| Fifty Two Week High Change Percent | -0.79965377 |
| Fifty Two Week Low | 7.46 |
| Fifty Two Week Low Change | 0.64000034 |
| Fifty Two Week Low Change Percent | 0.08579093 |
| Fifty Two Week Range | 7.46 - 40.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,761,571,800,000 |
| Float Shares | 16,051,368 |
| Forward Eps | -3.41885 |
| Forward P E | -2.3692179 |
| Free Cashflow | -95,213,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 133 |
| Fullday Change | 0.07999992 |
| Fullday Change Percent | 0.99750525 |
| Fullday Price | 8.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.52275 |
| Held Percent Institutions | 0.48801997 |
| Implied Shares Outstanding | 55,575,719 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-10-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. |
| Long Name | MapLight Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 450,163,360 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_605975835 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -229,827,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 603,552,307 |
| Number Of Analyst Opinions | 13 |
| Open | 8.1 |
| Operating Cashflow | -174,668,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Phone | 617 984 6300 |
| Previous Close | 8.02 |
| Price Eps Current Year | -1.7234044 |
| Price Hint | 2 |
| Price To Book | 1.0566137 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.794 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.46667 |
| Region | US |
| Regular Market Change | 0.07999992 |
| Regular Market Change Percent | 0.99750525 |
| Regular Market Day High | 8.1 |
| Regular Market Day Low | 8.1 |
| Regular Market Day Range | 8.1 - 8.1 |
| Regular Market Open | 8.1 |
| Regular Market Previous Close | 8.02 |
| Regular Market Price | 8.1 |
| Regular Market Time | 1,792,157,401 |
| Regular Market Volume | 12,737 |
| Return On Assets | -0.67112 |
| Return On Equity | -1.1155 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 52,848,208 |
| Shares Percent Shares Out | 0.056599997 |
| Shares Short | 3,148,094 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,426,509 |
| Short Name | MapLight Therapeutics, Inc. |
| Short Percent Of Float | 0.09770001 |
| Short Ratio | 5.74 |
| Source Interval | 15 |
| State | CA |
| Symbol | MPLT |
| Target High Price | 43.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 26.53846 |
| Target Median Price | 25.0 |
| Total Cash | 304,724,992 |
| Total Cash Per Share | 6.57 |
| Total Debt | 1,987,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.044725 |
| Two Hundred Day Average Change | -12.944725 |
| Two Hundred Day Average Change Percent | -0.61510545 |
| Type Disp | Equity |
| Volume | 12,737 |
| Website | https://www.maplightrx.com |
| Zip | 94,063 |